Genetico Center (MOEX: GECO), a pioneer in the introduction of preimplantation genetic testing (PGT) in Russia, has filed for registration of intellectual property rights for more than 62 objects of its own R&D related to PGT. Genetico Center was the first to begin introducing PGT technology into Russian practical healthcare since the company's founding in 2011.
As of early 2026, Genetico Center has received 34 patents in the field of PGT, with 28 patent applications pending. According to Rospatent data, medical technologies became the leading area in terms of number of applications filed in Moscow in 2024, with 944 applications submitted for inventions in this field.
PGT is used in IVF protocols and allows for the identification of a high risk of genetic abnormalities at the earliest possible stage, even before embryo transfer into the uterine cavity. PGT increases IVF efficiency, with pregnancy rates more than doubling. This allows families to achieve pregnancy and give birth to a child more quickly.
In Russia, the proportion of couples diagnosed with infertility ranges from 15% to 17%, with half of the cases associated with genetic problems affecting pregnancy development. According to WHO, 1% to 5% of newborns have genetic abnormalities. PGT is aimed at preventing genetic pathologies and treating infertility. According to the latest report from the Russian Association of Human Reproduction, 182,568 IVF cycles were performed in 2023, and every 7th IVF cycle in Russia is performed with PGT.
As of 2026, genetic testing of embryos for monogenic diseases (PGT-M) and structural chromosomal rearrangements (PGT-SR) has been included in the standard IVF procedure under Compulsory Health Insurance (CHI).
Genetico was founded to introduce new genetic research methods into healthcare for personalized prevention and treatment of genetic diseases. In the field of PGT, Genetico's laboratory is the undisputed leader in terms of the number of tests performed. Over 13 years of operation, more than 80,000 embryos have been tested for infertility treatment. According to statistics, an average of 2-3 embryos are tested per family undergoing IVF with PGT.
A distinctive feature of PGT-M for the prevention of genetic diseases is the creation of an individual test system for each family. According to the law on the protection of citizens' health, such test systems do not require special permission and are produced in licensed laboratories, which significantly simplifies the process of their application in practical healthcare. Using PGT-M technology, Genetico's specialists have helped healthy children be born in more than 400 families at high risk of monogenic pathology by creating personalized diagnostic test systems tailored to their unique genetic characteristics. Genetico's laboratory has developed test systems for diagnosing more than 140 different monogenic diseases. Over the years of operation, Genetico has analyzed more than 2,000 embryos using PGT-M, with approximately 1,000 recommended for transfer. The creation of a personalized test system takes approximately three to four months due to the complexity of developing individual solutions. For common genetic markers, standardized components are used, which accelerates the creation of solutions for families with similar characteristics.
"In 2011, I set a goal for myself and for Genetico to introduce accessible genetic screening for all families planning pregnancy," comments Arthur Isaev, founder of Genetico. "It is important that families at risk of having children with genetic diseases are informed about this in advance, at the pregnancy planning stage, not only when they give birth to a sick child. Genetico is patenting embryo diagnostic technologies that can reduce the risk of having children with genetic diseases by 30-50%. The Artgen Biotech Group, as a developer of gene therapy drugs for the treatment of genetic diseases, knows how long such drugs take to develop and how expensive they are. Even today, very substantial funds are spent on the treatment of orphan diseases. In 2025, more than RUB 218 billion was allocated to the 'Circle of Kindness' assistance fund to help seriously ill children."